NCT02315768: A reported trial by University of California, San Diego
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02315768 |
|---|---|
| Title | A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 26, 2015 |
| Completion date | Nov. 30, 2023 |
| Required reporting date | Nov. 29, 2024, midnight |
| Actual reporting date | July 18, 2024 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |